305 related articles for article (PubMed ID: 19261963)
1. Intricacies of bevacizumab-induced toxicities and their management.
Gressett SM; Shah SR
Ann Pharmacother; 2009 Mar; 43(3):490-501. PubMed ID: 19261963
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
3. Safety of bevacizumab in patients with metastatic breast cancer.
Hamilton EP; Blackwell KL
Oncology; 2011; 80(5-6):314-25. PubMed ID: 21778772
[TBL] [Abstract][Full Text] [Related]
4. Managing patients treated with bevacizumab combination therapy.
Gordon MS; Cunningham D
Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.
Akun E; Okutur K; Seber S; Korkmaz T; Aydin K; Bozkurt M; Namal E; Hasbal B; Tecimer C; Demir G
J BUON; 2012; 17(4):669-76. PubMed ID: 23335523
[TBL] [Abstract][Full Text] [Related]
6. Understanding and managing the possible adverse effects associated with bevacizumab.
Shord SS; Bressler LR; Tierney LA; Cuellar S; George A
Am J Health Syst Pharm; 2009 Jun; 66(11):999-1013. PubMed ID: 19451611
[TBL] [Abstract][Full Text] [Related]
7. [Generation mechanisms and management strategies of adverse reactions to Bevacizumab during cancer treatment].
Ge FJ; Xu JM
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):481-6. PubMed ID: 21029688
[No Abstract] [Full Text] [Related]
8. Adverse events in bevacizumab and chemotherapy: patient management.
Blowers E; Hall K
Br J Nurs; 2009 Apr 9-22; 18(7):424-8. PubMed ID: 19373187
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
Hurwitz H; Saini S
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events.
Wu S; Keresztes RS
Cancer Invest; 2011 Aug; 29(7):460-71. PubMed ID: 21740083
[TBL] [Abstract][Full Text] [Related]
11. Managing adverse events in the use of bevacizumab and chemotherapy.
Blowers E; Hall K
Br J Nurs; 2009 Mar 26-Apr 8; 18(6):351-6, 358. PubMed ID: 19329899
[TBL] [Abstract][Full Text] [Related]
12. Nursing considerations of bevacizumab use in multiple tumor types.
Gobel BH
Oncol Nurs Forum; 2007 May; 34(3):693-701. PubMed ID: 17573328
[TBL] [Abstract][Full Text] [Related]
13. [Surgical management of bevacizumab-associated peritonitis due to perforation].
Kube R; Meyer F; Bien N; Schmidt C; Mroczkowski P; Dalicho S; Lippert H
Zentralbl Chir; 2009 Sep; 134(5):462-7. PubMed ID: 19757347
[TBL] [Abstract][Full Text] [Related]
14. Managing bevacizumab-related toxicities in patients with colorectal cancer.
Saif MW
J Support Oncol; 2009; 7(6):245-51. PubMed ID: 20380333
[No Abstract] [Full Text] [Related]
15. Incidence and management of bevacizumab-related toxicities in colorectal cancer.
Saif MW; Mehra R
Expert Opin Drug Saf; 2006 Jul; 5(4):553-66. PubMed ID: 16774493
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal perforation due to bevacizumab in colorectal cancer.
Saif MW; Elfiky A; Salem RR
Ann Surg Oncol; 2007 Jun; 14(6):1860-9. PubMed ID: 17356952
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.
Thornton AD; Ravn P; Winslet M; Chester K
Br J Surg; 2006 Dec; 93(12):1456-63. PubMed ID: 17115389
[TBL] [Abstract][Full Text] [Related]
19. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies.
Zondor SD; Medina PJ
Ann Pharmacother; 2004; 38(7-8):1258-64. PubMed ID: 15187215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
